Abstract
Tripartite motif (TRIM) family proteins participate in a a TRIM67/p53 self-amplifying loop that boosts p53-induced variety of important cellular processes, including apoptosis, cell growth inhibition and apoptosis. Consequently, loss of cell-cycle arrest, DNA repair, and senescence. In this study, we this p53-positive regulatory program profoundly compro-demonstrated that a novel TRIM family member, TRIM67, was mised p53-mediated responses to chemotherapy-induced commonly silenced in colorectal cancer and its downregula-DNA damage. Dampened p53 response was also observed in tion was associated with poor survival. Trim67 knockout in tumors of Trim67 knockout mice and Trim67 knockout embry-ApcMin/þ mice increased the incidence, multiplicity, and bur-onic fibroblasts. TRIM67 reactivation restored p53 activation den of colorectal tumors. Similarly, colon-specific knockout of and sensitized colorectal cancer cells to chemotherapy in vitro Trim67 significantly accelerated azoxymethane-induced colo- and in vivo. TRIM67 thus functions as a pivotal tumor sup-rectal cancer in mice. RNA sequencing revealed that the anti-pressor in colorectal cancer and is a potential target for tumor effect of TRIM67 was mediated by activation of the p53 improving chemotherapy responsiveness. signaling pathway. TRIM67 interacted directly with the C-terminus of p53, inhibiting p53 degradation by its ubiquitin Significance: The TRIM67/p53 axis represents a novel ther-ligase MDM2. TRIM67 was also a transcriptional target of p53; apeutic target that could be harnessed to improve chemother-upon cellular stress, p53 bound to the TRIM67 promoter and apy efficacy in colorectal cancer expressing wild-type p53 but induced significant upregulation of TRIM67, thereby forming with repressed p53 signaling.
Original language | English |
---|---|
Pages (from-to) | 4086-4098 |
Number of pages | 13 |
Journal | Cancer Research |
Volume | 79 |
Issue number | 16 |
DOIs | |
State | Published - Aug 15 2019 |
Bibliographical note
Publisher Copyright:©2019 American Association for Cancer Research.
Funding
This study was supported by RGC-GRF Hong Kong (14111216, 14106415, 14163817); National Natural Science Foundation of China (NSFC; No.81572758); Science and Technology Program Grant Shenzhen (JCYJ20170413161534162); National Key Research and Development Program Fund China (2016YFC1303200); Grant from Faculty of Medicine CUHK on Microbiota Research, Vice-Chancellor's Discretionary Fund CUHK, CUHK direct grant, Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.
Funders | Funder number |
---|---|
RGC-GRF Hong Kong | 14106415, 14111216, 14163817 |
Shenzhen Research Institute, City University of Hong Kong | |
National Natural Science Foundation of China (NSFC) | 81572758 |
National Natural Science Foundation of China (NSFC) | |
Chinese University of Hong Kong | |
National Key Basic Research and Development Program of China | 2016YFC1303200 |
National Key Basic Research and Development Program of China | |
Shenzhen Virtual University Park | |
Yibin Science and Technology Planning Program | JCYJ20170413161534162 |
Yibin Science and Technology Planning Program |
ASJC Scopus subject areas
- Oncology
- Cancer Research